Podcast: Insilico's Co-CEO Talks AI, ChatGPT And The Future Of Drug Discovery
New Approach Starting From Patients
Executive Summary
After securing US orphan designation for an artificial intelligence-assisted therapeutic, Insilico's co-CEO Feng Ren sits down for a wide-ranging interview in which he discusses why AI drug discovery is more predictable, efficient and cost-effective than the conventional bench-to-bed model. AI's limitations and validations, why the industry should get excited about algorithms, data sets and deep learning are other topics to consider in this fast-growing field.